Showing results (11-20 of 213) with videos related to
Sort By:
Pageof 22
Chinese Clinical Oncology|March 3, 2016
Statistical aspect of translational and correlative studies in clinical trialsHerbert Pang, Xiaofei WangAnticancer Research|January 29, 2011
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancerNan Soon Wong, Nishan H Fernando, Andrew B Nixon, et al.Cancer Chemotherapy and Pharmacology|December 21, 2014
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumorsHope E Uronis, Jingquan Jia, Johanna C Bendell, et al.Molecular Cancer Therapeutics|February 20, 2015
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimusYingmiao Liu, Mark D Starr, John C Brady, et al.The Journal of Biological Chemistry|March 8, 2002
The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassemblyAndrew B Nixon, Gabriele Grenningloh, Patrick J CaseyGenetic Epidemiology|March 9, 2013
Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomesHerbert Pang, Sin-Ho JungGynecologic Oncology|September 3, 2014
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancerAngeles Alvarez Secord, Andrew B Nixon, Herbert I HurwitzEuropean Journal of Human Genetics : EJHG|March 4, 2011
Pathway-based identification of SNPs predictive of survivalHerbert Pang, Michael Hauser, Stéphane MinvielleBioinformatics (Oxford, England)|November 26, 2009
Pathway analysis using random forests with bivariate node-split for survival outcomesHerbert Pang, Debayan Datta, Hongyu ZhaoJournal of Statistical Planning and Inference|September 10, 2013
Statistical properties on semiparametric regression for evaluating pathway effectsInyoung Kim, Herbert Pang, Hongyu ZhaoPageof 22